New drug ProAgio tested in patients with advanced cancers
NCT ID NCT05085548
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug, ProAgio, in 46 people with advanced solid tumors, including pancreatic cancer, who had already tried other treatments. The main goal was to find a safe dose and check for side effects. The study did not aim to cure the disease, but to control it and gather information for future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Institute
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a Cancer-Fighting virus shrink resistant tumors?
- Can a targeted antibody slow advanced pancreatic cancer?
- ECMO in kids with cancer: a closer look at survival and risks
- New PET tracer could sharpen cancer detection
- Double-Drug attack on Hard-to-Treat cancers